.@methodsmanmd discusses a recent study that links the development of #Parkinson disease not to the brain but to the gut.

According to current evidence-based guidelines, liver-directed pharmacotherapy for MASH should be avoided in individuals with cirrhosis. Learn more about the latest guidance! ➡️

CKD is an important comorbidity of MASLD. A meta-analysis involving 28,000 individuals found that MASLD was associated with a 2-fold increased prevalence of CKD. Learn more about MASH Advances ➡️

📌 The FIB-4 score alone isn't enough to assess MASH risk, primarily in patients w/ T2DM or those age 65+. @SonalKumarMD with @AlkhouriNaim discuss the limits and non-invasive testing options that ID risk + progression. 𝐉𝐔𝐒𝐓 𝟏𝟑 𝐌𝐢𝐧𝐮𝐭𝐞𝐬! 🛑

T2DM is the strongest predictor of disease progression in MASH. FIB-4 can underestimate fibrosis risk, as even w/ a normal score, progression can be fast. @SonalKumarMD with @AlkhouriNaim explains noninvasive testing options in just 13 minutes! 📌

Weight loss of 3-5% improves steatosis, but >10% is needed to improve MASH and fibrosis. While sustained weight loss can be challenging, ongoing support and tailored interventions can help patients stay on track. Learn More About MASH Management! ➡️

📌 𝐖𝐚𝐭𝐜𝐡 𝐋𝐈𝐕𝐄 𝐢𝐧 𝟏 𝐇𝐎𝐔𝐑! ➡️ MASH is complex - but progress is being made. Tune in for a dynamic chat with Drs Alkhouri and Kumar as they tackle the role of NITs in risk stratification and what’s next in MASLD management.

📌 𝐖𝐚𝐭𝐜𝐡 𝐋𝐈𝐕𝐄 𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰! ➡️ MASH management is changing - fast. Join Drs. Alkhouri & Kumar as they explore how non-invasive tests are reshaping diagnosis, risk stratification, and the future of MASLD care. 📅 Join LIVE tomorrow.

𝐋𝐈𝐕𝐄 𝐨𝐧 𝐖𝐞𝐝𝐧𝐞𝐬𝐝𝐚𝐲 ➡️ Can NITs change the game in MASH management?. Drs. Alkhouri and Kumar break down how non-invasive tools are transforming patient risk stratification, and what it means for real-world clinical practice. Don’t miss out!

Tobacco use + T2DM = a higher risk of fibrosis in MASLD. Be sure to screen your patients who smoke regularly as smoking accelerates liver disease progression, making early detection critical. Don't Miss New MASH Advances! ➡️

📌 𝐂𝐨𝐦𝐢𝐧𝐠 𝐒𝐨𝐨𝐧. Noninvasive tests (NITs) are transforming how we identify risk in MASH. Join top voices in the field as they explore the latest strategies in MASLD and MASH care. 📅 LIVE on June 11 – Be part of the conversation. ➡️

In MASH, the FAST score helps identify patients at risk for progression. This noninvasive tool combines markers of steatosis (CAP), inflammation (ACT), and fibrosis (VCTE) to guide clinical decisions. Learn the Latest! ➡️

📚 Ready to level up your GERD knowledge? Understand key differences in GERD types and explore new acid-suppressive agents to improve outcomes. Don’t miss it!.🔗

𝐈𝐂𝐘𝐌𝐈! ACG's 1st update to H. pylori treatment guidelines since 2017 include Bismuth quadruple therapy (BQT) as the preferred 1st-line regimen. @umfoodoc @DrVivianAsamoah @ShailjaShahMD share how to optimize for practice! ⭐

🧪 Explore key differences between erosive & non-erosive GERD and review the latest evidence on acid-suppressive agents. Strengthen your GERD treatment plans with new options and clinical confidence! .🔗 . #GERD #GIHealth #AcidSuppression

🚩 Quickly ID high-risk patients for MASLD / MASH using FIB-4 calculator in clinic. Dr Shubrook + @AlkhouriNaim explain how this flags patients who need crucial attention, or confirms ongoing metabolic management. Watch this 15-minute MASH MASTERS ➡️

🌀 GLP-1s can have confusing and frustrating gastro side effects, as patients can experience constipation, diarrhea, or even both!. Watch 𝗚𝗲𝘁𝘁𝗶𝗻𝗴 𝗦𝗼𝗰𝗶𝗮𝗹 𝗔𝗯𝗼𝘂𝘁 𝗖𝗼𝗻𝘀𝘁𝗶𝗽𝗮𝘁𝗶𝗼𝗻 to help them get relief! ➡️

In patients w/ T2DM, pre-T2DM, or ≥2 metabolic risk factors, FIB-4 should be assessed every 1-2 years (if initial FIB-4 is <1.3) to enable early detection of fibrosis progression and timely intervention. Learn more about MASH Advances➡️

𝐈𝐂𝐘𝐌𝐈! ACG's 1st update to H. pylori treatment guidelines since 2017 include Bismuth quadruple therapy (BQT) as the preferred 1st-line regimen. @umfoodoc @DrVivianAsamoah @ShailjaShahMD share how to optimize for practice! ⭐

𝐖𝐀𝐓𝐂𝐇 𝐋𝐈𝐕𝐄 𝐢𝐧 𝟏 𝐇𝐎𝐔𝐑! @umfoodoc @DrVivianAsamoah @ShailjaShahMD explain how to update your daily practice to align with the ACG's 2024 clinical guidelines for treating H pylori, still the world’s most common chronic bacterial infection.

🟢 What is the biggest challenge you face when managing H. pylori infection in your patient population?. 𝐖𝐀𝐓𝐂𝐇 𝐋𝐈𝐕𝐄 𝐓𝐎𝐌𝐎𝐑𝐑𝐎𝐖! @umfoodoc @DrVivianAsamoah @ShailjaShahMD explain ACG's updated clinical guidelines for treating H pylori. ➡️